News | May 22, 2024
AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
Launch of 20 new medicines expected by 2030
Launch of 20 new medicines expected by 2030
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The award recognizes powerful science–industry collaborations for social good
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
EBITDA before special items falls 1.3 percent to € 4.41 billion
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
